The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Karyopharm Therapeutics
Selinexor (SEL) plus ruxolitinib (RUX) in JAK inhibitor (JAKi) treatment-naïve patients with myelofibrosis: Updated results from XPORT-MF-034.
 
Haris Ali
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb
 
Ashwin Kishtagari
No Relationships to Disclose
 
Keri Renee Maher
Consulting or Advisory Role - SOBI
 
Sanjay Mohan
Research Funding - Incyte (Inst); Karyopharm Therapeutics (Inst); Taiho Pharmaceutical (Inst)
 
Josef T. Prchal
No Relationships to Disclose
 
Xulong Wang
Employment - Karyopharm Therapeutics
 
Kamal Chamoun
No Relationships to Disclose
 
Srinivas Kiran Tantravahi
Honoraria - Karyopharm Therapeutics
Consulting or Advisory Role - Karyopharm Therapeutics
Research Funding - Karyopharm Therapeutics